Enlivex Therapeutics Ltd Financials
This page shows Enlivex Therapeutics Ltd (ENLV) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Enlivex Therapeutics Ltd passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Enlivex Therapeutics Ltd generates $0.87 in operating cash flow (-$13.0M OCF vs -$15.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Enlivex Therapeutics Ltd's EBITDA was -$15.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 46.3% from the prior year.
Enlivex Therapeutics Ltd generated -$13.1M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 44.8% from the prior year.
Enlivex Therapeutics Ltd reported -$15.0M in net income in fiscal year 2024. This represents an increase of 48.3% from the prior year.
Enlivex Therapeutics Ltd earned $-0.73 per diluted share (EPS) in fiscal year 2024. This represents an increase of 53.2% from the prior year.
Enlivex Therapeutics Ltd held $3.3M in cash against $0 in long-term debt as of fiscal year 2024.
Enlivex Therapeutics Ltd had 24M shares outstanding in fiscal year 2024. This represents an increase of 27.2% from the prior year.
Enlivex Therapeutics Ltd invested $10.6M in research and development in fiscal year 2024. This represents a decrease of 44.1% from the prior year.
Enlivex Therapeutics Ltd invested $103K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 56.4% from the prior year.
ENLV Income Statement
| Metric | Q2'25 | Q2'24 | Q4'23 | Q2'23 | Q4'22 | Q2'22 | Q4'21 | Q2'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $2.1M+7.1% | $2.0M | N/A | $5.0M | N/A | $4.1M | N/A | $2.5M |
| SG&A Expenses | $937K-5.1% | $987K | N/A | $1.6M | N/A | $1.8M | N/A | $1.3M |
| Operating Income | -$3.1M-3.1% | -$3.0M | N/A | -$6.6M | N/A | -$5.9M | N/A | -$3.8M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$1.9M+39.7% | -$3.1M | N/A | -$6.8M | N/A | -$9.9M | N/A | -$3.1M |
| EPS (Diluted) | $-0.08+50.0% | $-0.16 | N/A | $-0.37 | N/A | $-0.54 | N/A | $-0.17 |
ENLV Balance Sheet
| Metric | Q2'25 | Q2'24 | Q4'23 | Q2'23 | Q4'22 | Q2'22 | Q4'21 | Q2'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $22.6M-18.4% | $27.7M-24.8% | $36.8M-30.5% | $53.0M-21.6% | $67.6M-12.5% | $77.3M-18.7% | $95.1M0.0% | $95.2M |
| Current Assets | $21.3M-18.0% | $26.0M-23.0% | $33.8M+9.7% | $30.8M-41.2% | $52.3M-19.6% | $65.1M-24.7% | $86.4M-6.9% | $92.8M |
| Cash & Equivalents | $1.9M-42.7% | $3.3M+306.0% | $813K-76.5% | $3.5M-93.1% | $49.9M+147.9% | $20.2M+79.9% | $11.2M-11.2% | $12.6M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.5M-13.5% | $4.1M-39.3% | $6.7M-22.4% | $8.7M-19.5% | $10.8M+22.0% | $8.9M-12.4% | $10.1M+102.9% | $5.0M |
| Current Liabilities | $3.3M-12.4% | $3.8M-37.3% | $6.1M+21.4% | $5.0M-24.5% | $6.6M+56.8% | $4.2M-10.7% | $4.7M+3.1% | $4.6M |
| Long-Term Debt | N/A | N/A | N/A | $7.2M | N/A | N/A | N/A | N/A |
| Total Equity | $19.1M-19.2% | $23.6M-21.6% | $30.1M-32.1% | $44.3M-22.0% | $56.8M-17.0% | $68.5M-19.5% | $85.0M-5.7% | $90.2M |
| Retained Earnings | -$132.4M-4.2% | -$127.1M-13.4% | -$112.1M-15.5% | -$97.0M-16.9% | -$83.0M-18.4% | -$70.1M-34.9% | -$52.0M-18.6% | -$43.8M |
ENLV Cash Flow Statement
| Metric | Q2'25 | Q2'24 | Q4'23 | Q2'23 | Q4'22 | Q2'22 | Q4'21 | Q2'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ENLV Financial Ratios
| Metric | Q2'25 | Q2'24 | Q4'23 | Q2'23 | Q4'22 | Q2'22 | Q4'21 | Q2'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -8.3%+1.4pp | -9.7% | N/A | -12.8% | N/A | -12.8% | N/A | -3.3% |
| Current Ratio | 6.41-0.4 | 6.84+1.3 | 5.57-0.6 | 6.17-1.8 | 7.92-7.5 | 15.44-2.9 | 18.32-2.0 | 20.29 |
| Debt-to-Equity | 0.19+0.0 | 0.17-0.1 | 0.22+0.1 | 0.16-0.0 | 0.19+0.1 | 0.13+0.0 | 0.12+0.1 | 0.06 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Enlivex Therapeutics Ltd profitable?
No, Enlivex Therapeutics Ltd (ENLV) reported a net income of -$15.0M in fiscal year 2024.
What is Enlivex Therapeutics Ltd's earnings per share (EPS)?
Enlivex Therapeutics Ltd (ENLV) reported diluted earnings per share of $-0.73 for fiscal year 2024. This represents a 53.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Enlivex Therapeutics Ltd's EBITDA?
Enlivex Therapeutics Ltd (ENLV) had EBITDA of -$15.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Enlivex Therapeutics Ltd's free cash flow?
Enlivex Therapeutics Ltd (ENLV) generated -$13.1M in free cash flow during fiscal year 2024. This represents a 44.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Enlivex Therapeutics Ltd's operating cash flow?
Enlivex Therapeutics Ltd (ENLV) generated -$13.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Enlivex Therapeutics Ltd's total assets?
Enlivex Therapeutics Ltd (ENLV) had $27.7M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Enlivex Therapeutics Ltd's capital expenditures?
Enlivex Therapeutics Ltd (ENLV) invested $103K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Enlivex Therapeutics Ltd spend on research and development?
Enlivex Therapeutics Ltd (ENLV) invested $10.6M in research and development during fiscal year 2024.
How many shares does Enlivex Therapeutics Ltd have outstanding?
Enlivex Therapeutics Ltd (ENLV) had 24M shares outstanding as of fiscal year 2024.
What is Enlivex Therapeutics Ltd's current ratio?
Enlivex Therapeutics Ltd (ENLV) had a current ratio of 6.84 as of fiscal year 2024, which is generally considered healthy.
What is Enlivex Therapeutics Ltd's debt-to-equity ratio?
Enlivex Therapeutics Ltd (ENLV) had a debt-to-equity ratio of 0.17 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Enlivex Therapeutics Ltd's return on assets (ROA)?
Enlivex Therapeutics Ltd (ENLV) had a return on assets of -54.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Enlivex Therapeutics Ltd's cash runway?
Based on fiscal year 2024 data, Enlivex Therapeutics Ltd (ENLV) had $3.3M in cash against an annual operating cash burn of $13.0M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Enlivex Therapeutics Ltd's Piotroski F-Score?
Enlivex Therapeutics Ltd (ENLV) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Enlivex Therapeutics Ltd's earnings high quality?
Enlivex Therapeutics Ltd (ENLV) has an earnings quality ratio of 0.87x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.